INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

O'Neill Gilmore Neil sold EDIT

Director, CEO · Editas Medicine, Inc. · Common Stock

Side
SELL
Value
$16K
Shares
5,124
Price
$3.04
Executed
Sep 3, 2026
Disclosed
Sep 4, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 3 executedSep 4, 2026 disclosed

EDIT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
11/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $16K reported value · 2.1% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · EDIT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    OS
    Ory Daniel ScottEVP, Chief Medical Officer
    EDITEditas Medicine, Inc.
    Grant or award
    		A—
    950.0K sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    11
    PA
    Parison AmySVP, Chief Financial Officer
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,376
    453 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    11
    BL
    Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,153
    709 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    ET
    Ellinor Patrick Thomas IIDirector
    EDITEditas Medicine, Inc.
    Grant or award
    		A—
    103.4K sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    15
    BL
    Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,535
    713 sh
    		Dec 3, 2025Dec 4, 2025
    traded Dec 3, 2025
    		+1dSEC FORM 4

    Evidence

    15
    ON
    O'Neill Gilmore NeilDirector, CEO
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$12K
    5,603 sh
    		Dec 3, 2025Dec 4, 2025
    traded Dec 3, 2025
    		+1dSEC FORM 4

    Evidence

    15
    PA
    Parison AmySVP, Chief Financial Officer
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$993
    461 sh
    		Dec 3, 2025Dec 4, 2025
    traded Dec 3, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001742084-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 3, 2026
    Published
    Sep 4, 2026
    Ingested by INSIDER
    Nov 5, 02:18 UTC
    Last re-read
    Nov 5, 02:18 UTC

    Extracted facts

    Filer
    O'Neill Gilmore Neil
    Role
    Director, CEO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Editas Medicine, Inc.
    Ticker
    EDIT
    Shares
    5,124
    Price per share
    $3.04
    Value
    $15,563
    Execution date (reported)
    Sep 3, 2026
    Owned after transaction
    243.2K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 5,124
    • Price: $3.0372

    = $15,563

    What this establishes

    O'Neill Gilmore Neil filed this Form 4 reporting a open-market sale of EDIT on Sep 3, 2026. It became public on Sep 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO
    O'Neill Gilmore Neilcik:0001742084
    Issuer
    Editas Medicine, Inc.cik:0001650664

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.